Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Automated microscopy and image analysis
Real-time, label free cell analysis
Nano and micro particle analysis

Accelerate to discover
Related topics
Standardize tumor sample preparation and reduce background with Curiox laminar wash system
Aug 10, 2022
Laminar Wash technology offers a gentle alternative that can improve yield and data quality, particularly of rare cell...
Developing a 43 color panel on Cytek Aurora using Laminar Wash for sample prep
Aug 2, 2022
Successfully executing a 43 color panel is a technically demanding task. One that is made more difficult when there are...
Intoducing spheroOne: Automated sorting and isolation of single spheroids and organoids
Jun 21, 2022
spheroONE is an innovative single large-particle sorter and dispenser which revolutionizes 3D cellular models handling....
Outstanding post-sort sample recovery on the WOLF Cell Sorter
Jun 14, 2022
The new WOLF G2 instrument has significantly expanded the capabilities of gentle benchtop microfluidic cell sorting...
Incucyte AI module: Advanced Label-Free Classification Analysis
Jun 6, 2022
Monitor adherent cell morphology changes objectively to determine live/dead cell counts or classify cells based on...
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters
Jun 3, 2022
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine...
An experimental strategy for preparing circular ssDNA virus genomes for next-generation sequencing
Jun 1, 2022
Recent article from February 2022 shoes how size selection improved viral read mapping by over 90% for begomoviruses.
Intoducing cellenONE: The revolutionary Single Cell isolator
May 25, 2022
A revolutionary platform based on sciDROP PICO precision dispensing technology and coupled with advanced image...
Mar 22, 2016
Over the last two decades, a number of blockbuster drugs have been withdrawn or have incurred safety warnings by regulatory agencies due to adverse cardiac effects. In addition, lead compounds or drug candidates are frequently terminated at late stages of drug development due to cardiac safety concerns. Both of these factors can significantly impact the overall cost of drug discovery; consequently, pharmaceutical companies and regulatory agencies have implemented procedures to address these issues.
Most, if not all, in vitro assay systems for cardiac safety are designed to screen for surrogates of arrhythmia, such as hERG channel interaction, rather than arrhythmia itself. Assays designed to screen for compounds that may affect repolarization and induce arrhythmia in the context of the whole heart or heart tissue are not implemented until much later in drug development. These include sophisticated, technically demanding, lowthroughput, and costly procedures such as the Purkinje fiber assay, ventricular wedge assay, and the Langendorff whole heart assay, or telemetry experiments in live and anesthetized animals. The field of preclinical cardiac safety can certainly benefit from an assay system that allows for integrated assessment of compound action on ion channel and non-ion channel targets involved in cardiac excitation-contraction coupling.
The RTCA Cardio Instrument in conjunction with iCell Cardiomyocytes comprises an assay system providing integrated assessment of compound action on multiple targets involved in heart function. This assay system can sensitively and quantitatively detect the effect of compounds on the major ion channels involved in heart function, namely calcium, sodium, and potassium channels. Another major advantage of the assay system is the time resolution. The RTCA Cardio Instrument has a data acquisition rate of 12.5 ms per well of a 96-well plate and can be used simultaneously to monitor acute and chronic drug effects up to days and weeks. The utility of the time-dependent monitoring of compound action on cardiomyocytes can be demonstrated by testing compounds that acutely and directly block hERG channels (E4031, cisapride, etc.) and compounds that interfere with protein trafficking (pentamidine) in a sub-chronic manner. The RTCA Cardio Instrument is able to detect the effects of these compounds on the beating rate and duration of iCell Cardiomyocytes.
The xCELLigence System RTCA Cardio Instrument, in conjunction with iCell Cardiomyocytes, represents a physiologically relevant and predictive assay system for preclinical cardio-safety assessment of lead compounds. The features of this assay system, including time resolution, dynamic monitoring of mechanical beating activity of cardiomyocytes, and 96-well throughput, will surely provide additional mechanistic and toxicity information for compound action on the heart.
Related technologies: Real-time, label free cell analysis
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com